SEARCH

SEARCH BY CITATION

References

  • 1
    Colaizzi JL, Lowenthal DT., Critical therapeutic cat-egories: a contraindication to generic substitution? Clin Ther. 1986; 8 4 370379.
  • 2
    Nightingale SL., From the Food and Drug Adminis-tration. JAMA. 1998; 279 9 645.
  • 3
    Mahalati K, Panek R, West K, Sketris I, Belitsky P. Can “area under the curve” based on abbreviated pharmacokinetics be used for cyclosporine micro-emulsion (Neoral) monitoring in kidney transplant recipients? Transplantation. 1998; 65 (suppl 5): 81.
  • 4
    Laskow DA, Vincenti F, Nevlan JF, Mendez R, Matas AJ., An open-label, concentration ranging trial of FK506 in primary kidney transplanta-tion: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation. 1996; 62 7 900905.
  • 5
    Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclo-sporine pharmacokinetics in renal transplant recipients treated with a microemulsion for-mulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation. 1995 59(4): 505511.
  • 6
    Cavanak T, Cyclosporin Sucker H. Formulation of dosage forms. Prog Allergy. 1986; 38: 6572.
  • 7
    Carter BL, Noyes MA, Demmler RW., Differences in serum concentrations of and responses to generic verapamil in the elderly. Pharmacotherapy. 1993; 13 4 359368.
  • 8
    Roza A, Tomlanovich S, Merion R, et al. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation. 2002; 74 7 10131017.
  • 9
    Taber DJ, Baillie GM, Ashcraft EE, et al. Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation. 2005; 80 11 16331635.
  • 10
    Helderman JH, Kang N, Legoretta A, et al. Health-care costs to renal transplant recipients using branded v. generic cyclosporine. Appl Health Economics. 2010; 8: 6168.
  • 11
    Kim SJ, Huh KH, Han DJ, et al. A 6-month, multi-center, single-arm pilot study to evaluate the effi-cacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation. Transplant Proc. 2009; 41 5 16711674.
  • 12
    Alloway RR, Isaccs R, Lake K., Report of the American Society of Transplantation Conference on Immunosuppressive Drugs and the Use of Generic Immunosuppressants. Am J Transplant. 2003; 3: 12111215.
  • 13
    Johnston A, Belitsky P, Freiv, et al. Potential clinical implications of substitution of generic cyclospo-rine formulations for cyclosporine microemulsion (Neoral) in transplant recipients. Eur J Clin Phar-macol. 2004; 60 6 389395.
  • 14
    Sabatini S, Ferguson RM, Helderman JH, Hull AR, Kirkpatrick BS, Barr WH., Drug substitution in transplantation: a National Kidney Foundation White Paper. Am J Kidney Dis. 1999; 33 2 389397.
  • 15
    Sketris I, Yatscoff R, Keown P, et al. Optimizing the use of cyclosporine in renal transplantation. Clin Biochem. 1995; 28 3 195211.